Celgene At $100: Buy, Sell, or Hold?
It's been a rotten couple of weeks to be a shareholder of Celgene (NASDAQ: CELG). The biotech giant's shares have been in near-freefall after they reached an all-time high of $147 on Oct. 2. Investors who bought at the peak have lost more than 33% in a matter of weeks. Ouch.
A drop of that magnitude begs the question: Should investors buy the dip, or is the bull case for owning this stock busted?
Image source: Getty Images.
Source: Fool.com
